Answers are grounded in this paper and cite their sources.
Explores controlled translation of circular RNAs in various contexts, suggesting new therapeutic strategies.
Circular RNAs (circRNAs) have emerged as a promising platform for RNA-based therapeutics, ascribed to their excellent stability and prolonged protein translation capacity. However, modulation of circRNA translation remains a great challenge. Here, we develop a new chemically regulated circRNA translation system based on small ligand-induced stabilization of RNA-binding proteins (RBPs). The system is engineered by incorporating RNA motifs into an internal ribosomal entry site and fusing RBPs with small ligand-stabilized conditional proteins. We show that this design allows small ligand-modulated translation of circRNAs with a wide dynamic range and dose dependency. It is demonstrated that this strategy is modular and versatile to different RBPs and small-ligand-stabilized conditional proteins. We further employ this strategy to control the translation of functional proteins, including a guanine nucleotide exchange factor for modulating signaling pathways and a bispecific engager for regulating T cell activities. This system is highly modular and versatile, highlighting its great potential for basic research and therapeutic applications.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: